<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459029</url>
  </required_header>
  <id_info>
    <org_study_id>043211- HMO-CTIL</org_study_id>
    <nct_id>NCT01459029</nct_id>
  </id_info>
  <brief_title>High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia</brief_title>
  <acronym>SATROS</acronym>
  <official_title>High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia : A Randomized, Double-Blind, Placebo-Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herzog Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare efficacy and safety of add-on treatment with a&#xD;
      moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset&#xD;
      schizophrenia patients who suffer from significant symptoms despite treatment with&#xD;
      antipsychotics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Recent advances in understanding the neurobiology underlying schizophrenia have&#xD;
      underscored a pivotal role for a specific receptor for the neurotransmitter glutamate, the&#xD;
      NMDA receptor, whose function may be impaired in the disorder. Enhancing transmission at the&#xD;
      NMDA receptor may therefore provide a novel mechanism for treating schizophrenia. Over the&#xD;
      past decade clinical trials that included supplementation with different compounds enhancing&#xD;
      transmission at the NMDA receptor have provided positive results, particularly with D-serine.&#xD;
      However, none of these trials focused specifically on young patients with recent onset&#xD;
      schizophrenia. In addition, the optimal D-serine dose was not determined, although a&#xD;
      preliminary report suggested that higher doses than those used in most studies may provide&#xD;
      additional benefit, without significant safety concerns or side effects. Also, the&#xD;
      pro-cognitive effects of D-serine were not systematically analyzed, although preliminary data&#xD;
      supports a potential role for D-serine in ameliorating the cognitive deficits found in&#xD;
      schizophrenia.&#xD;
&#xD;
      Research Design: Over a two year period, 54 patients, male or female, aged 18-30 years who&#xD;
      fulfill DSM-IV criteria for schizophrenia or schizoaffective disorder, will be entered into a&#xD;
      12 week, parallel group, double blind, randomized controlled trial assessing the efficacy of&#xD;
      placebo vs. DSR (up to 6000 mg/day) augmentation to standard antipsychotic therapy. First&#xD;
      episode patients, and patients treated with clozapine, will be randomized separately.&#xD;
      Patients will be entered into the trial in accordance with strict inclusion and exclusion&#xD;
      criteria after the nature of the study has been explained to them and they have given written&#xD;
      informed consent. Clinical evaluations will be performed at baseline and then at regular&#xD;
      intervals during the trial. In addition, neurocognitive evaluations, electrophysiological&#xD;
      assessments and determination of amino acids levels will be conducted at the beginning and&#xD;
      end of the study. Treatment emergent adverse effects will be monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Total Score of the Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Subscales of PANSS</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Clinical Global Impressions (CGI)</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Scale for the Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Calgary Depression Scale for Schizophrenia (CDSS</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Quality of Life Scale (QOL)</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Simpson-Angus Extrapyramidal Rating Scale (SAS)</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Abnormal Involuntary Movement Scale (AIMS)</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Udvalg for Kliniske Undersgelser (UKU) Side Effect Rating Scale</measure>
    <time_frame>Biweekly for 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the Prepulse Inhibition (PPI) of Startle</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients with schizophrenia and their relatives may exhibit deficits in this operational measure of sensorimotor gating</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino Acid Serum Levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Glutamate, Glycine, D-serine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>D-serine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>D-serine up to 6000 mg/day subject to tolerability</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment with inert capsules (placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-serine</intervention_name>
    <description>Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>D-serine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-30&#xD;
&#xD;
          -  Diagnosis of schizophrenia/schizoaffective disorder&#xD;
&#xD;
          -  Recent onset (up to five years since onset of positive symptoms)&#xD;
&#xD;
          -  Stable dose antipsychotic treatment for at least 4 weeks&#xD;
&#xD;
          -  Baseline PANSS total score of at least 70&#xD;
&#xD;
          -  Baseline PANSS negative subscale score of at least 20&#xD;
&#xD;
          -  Clinically stable (stable CGI score for two consecutive weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Criteria for other DSM-IV Axis I diagnoses are met&#xD;
&#xD;
          -  Lifetime history of alcohol or substance dependence&#xD;
&#xD;
          -  Alcohol or substance abuse within the past year&#xD;
&#xD;
          -  Judged clinically to be at suicidal or homicidal risk&#xD;
&#xD;
          -  Female patients who are pregnant or lactating.&#xD;
&#xD;
          -  Patients with known intolerance to D-serine treatment&#xD;
&#xD;
          -  Patients treated with ECT within 12 weeks prior to study entry&#xD;
&#xD;
          -  Patients treated with TMS within 4 weeks prior to study entry&#xD;
&#xD;
          -  Patients suffering from an unstable and/or untreated medical disorder&#xD;
&#xD;
          -  Patients suffering from renal or hepatic dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Lotan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Lerer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uriel Heresco-Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ezrath Nashim - Herzog Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amit Lotan, MD</last_name>
    <phone>00 972 2 6777184</phone>
    <email>amitlo@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bernard Lerer, MD</last_name>
    <phone>00 972 2 6777185</phone>
    <email>lerer@cc.huji.ac.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ezrath Nashim - Herzog Memorial Hospital &amp; Community Clinics</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Uriel Heresco-Levy, MD</last_name>
      <phone>00 972 2 5316906</phone>
      <email>heresco@md.huji.ac.il</email>
    </contact>
    <investigator>
      <last_name>Uriel Heresco-Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raz Levin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Arik Tzukert, DMD</last_name>
      <phone>00 972 2 6776095</phone>
      <email>arik@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hadas Lemberg, PhD</last_name>
      <phone>00 972 2 6777572</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Amit Lotan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pablo Roitman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rina Cooper-Kazaz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>October 9, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>October 24, 2011</last_update_submitted>
  <last_update_submitted_qc>October 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <keyword>NMDA receptor</keyword>
  <keyword>D-serine</keyword>
  <keyword>Recent onset</keyword>
  <keyword>Negative symptoms</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

